Reported / Citable
Background
Relators, former employees of Advanced Pain Care (APC), brought a qui tam lawsuit under the federal False Claims Act (FCA) and the Texas Medicaid Fraud Prevention Act. They alleged that medical technology company Abbott Laboratories provided illegal kickbacks to APC and its lead physician, Dr. Mark Malone, to induce them to use Abbott’s Spinal Cord Stimulator (SCS) devices. The relators claimed Abbott provided “near-daily” meals at high-end restaurants, paid for office parties and personal events, and provided a company credit card for office expenses.
According to the complaint, these kickbacks, which are prohibited by the Anti-Kickback Statute (AKS), tainted the subsequent claims APC submitted to government healthcare programs like Medicare. Under the FCA, claims for payment that are induced by illegal kickbacks are considered false claims. By the time of this ruling, APC, Dr. Malone, and another corporate defendant had been dismissed, leaving Abbott as the sole remaining defendant.
Abbott moved to dismiss the case, arguing that the relators failed to plead their allegations with the specificity required by law. Specifically, Abbott contended the complaint did not adequately allege that its actions actually caused the submission of any false claims to the government or that it acted with the requisite fraudulent intent (scienter).
The Court’s Holding
United States Magistrate Judge Dustin M. Howell recommended that the District Judge grant Abbott’s motion to dismiss. The court found that the relators’ complaint failed to meet the heightened pleading standard of Federal Rule of Civil Procedure 9(b), which requires that allegations of fraud be stated with particularity.
The court explained that under Fifth Circuit precedent, an FCA relator must either identify the details of an actual false claim submitted to the government or, failing that, allege “particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were actually submitted.” Here, the relators did not identify a single specific false claim. Instead, they relied on estimates, such as that 55-60% of APC’s stimulator implantations were paid for by government insurance. The court held that such statistical estimates are not “reliable indicia” and are insufficient to satisfy Rule 9(b).
Furthermore, the court found the allegations did not plausibly establish a causal link between Abbott’s alleged kickbacks and the submission of false claims. The relators’ own complaint stated that Dr. Malone held an “expansive view” on the viability of SCS therapy and encouraged staff to “do whatever [they] could to persuade patients,” a position that was independent of and even contrary to Abbott’s own guidance. This suggested that APC might have submitted the claims regardless of any inducement from Abbott, breaking the causal chain necessary for Abbott’s liability under the FCA. The court declined to grant leave to amend the complaint and recommended dismissal of the related state-law claim as well.
Key Takeaways
- A False Claims Act complaint based on an alleged kickback scheme must plead facts with particularity that create a strong inference that specific false claims were actually submitted to the government as a result of the scheme.
- General statistical estimates regarding the proportion of a provider’s patients covered by government programs are not, by themselves, “reliable indicia” sufficient to meet the Rule 9(b) heightened pleading standard in the Fifth Circuit.
- An FCA claim against a manufacturer may be dismissed if the complaint contains facts suggesting that the medical provider had an independent motivation to submit the claims in question, thereby weakening the allegation that the manufacturer’s kickbacks caused the submission of false claims.
Why It Matters
This report and recommendation reinforces the stringent pleading requirements for False Claims Act cases, particularly those brought by private whistleblowers (relators) in the Fifth Circuit. It underscores that alleging a fraudulent kickback scheme is not enough; a plaintiff must also provide particular, plausible facts demonstrating that the scheme actually led to the government being defrauded through the submission of specific false claims.
The decision highlights a key challenge for relators in AKS-based FCA litigation: proving causation. The court’s focus on the physician’s independent motivations shows that defendants can defeat a claim at the pleading stage by pointing to alternative explanations for their conduct, even if those explanations are contained within the plaintiff’s own complaint. This ruling serves as a guide for litigants on the level of detail required to connect alleged kickbacks to the ultimate submission of a false claim for payment.